Learn about clinical trials that are currently recruiting.

— Phase 3 NASH Study
— Phase 4 PBC Study
— Phase 2 Biliary Atresia Study


At Intercept, our work is motivated by our desire to help patients and families who struggle with chronic liver diseases and need better treatment options.

Research & Development


Research is shedding light on the complex and powerful connection between bile acid and the farnesoid X receptor (FXR). Understand the metabolic effects of FXR.

Therapeutic Areas

Intercept is exploring FXR agonism and its effects throughout the body. Find out more about where our research is leading us.

Investigator Initiated Research

Intercept supports independent, unsolicited research related to progressive non-viral liver diseases. Submit a proposal for consideration.


Intercept is expanding its pipeline to feature new indications for liver diseases with limited therapeutic options. Take a look at the direction we are going.

Discovery Compounds

Intercept is focused on developing our lead compound, obeticholic acid, but we are also looking into the future with 2 novel compounds.


View scientific presentations for detailed clinical information about Intercept’s proprietary bile acid chemistry.

You are now leaving interceptpharma.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharma’s site or click ‘Continue’ to proceed. 

You are now being redirected to Intercept's job application site, hosted by a third party.